What were the results of the Angiotensin-Converting Enzyme Inhibitors (ACEi) and Kidney Protection (AIPRI) trial?
The Angiotensin-Converting Enzyme Inhibitors and Kidney Protection (AIPRI) trial compared benazepril to placebo in patients with CKD mostly without diabetes to assess its effect on CKD progression (doubling of serum creatinine or ESKD as the primary outcome). Benazepril caused a 53% reduction of the composite outcome, ESKD and a doubling of serum creatinine with 769 participants.